The CM Group Acquires Scientific Commercialization

The CM Group expands its offerings to the Life Sciences industry by offering Medical Affairs Consulting and Analytics.

HINGHAM, Mass.–(BUSINESS WIRE)–The CM Group, LLC, a leading provider of information and knowledge services to the biopharmaceutical community, announces the acquisition of Scientific Commercialization, LLC (SC), a Madison, Wisconsin-based leader in medical affairs consulting and business intelligence software solutions. The acquisition will offer a significant advantage to life science companies by providing a comprehensive suite of offerings coupled with the personalized, high-touch service both companies are known for.

“By combining SC’s core competencies with those of The CM Group, we are able to help our clients in a more comprehensive way,” explains The CM Group’s cofounder, Cherie Myatt. “The addition of SC’s medical consulting and BI capabilities uniquely positions us to provide our clients with customized solutions along with strategic and tactical capabilities ranging from early clinical and medical engagement through commercialization, based on their stage of development and specific needs.”

Scientific Commercialization provides innovative consulting and analytics to medical affairs and other functions within life sciences and biopharmaceutical companies, including a wide range of services from product strategy, launch and execution to organizational design and process optimization. In addition, they offer a robust suite of business intelligence solutions—including SC-Insight®, social listening and Natural Language Processing—empowering clients to optimize data and bring forward insights that provide real impact to patient and company success.

“I am particularly excited about the business intelligence capabilities that are now integrated into our offering,” explains Maggie Butler, cofounder of The CM Group. “We are now able to expand our capabilities and leverage insights to help our clients design programs that improve engagement with health care professionals and patient communities.”

The acquisition of Scientific Commercialization is the next step in The CM Group’s growth strategy. In 2017, the company launched the Px Group, a division focused on integrating authentic patient and caregiver voices through all stages of a company’s pre-commercial and commercial activities. Activities includes patient/caregiver advisory boards, 1:1 insight sessions, peer-to-peer meetings, mentor/buddy programs, advocacy relationship management, patient story development, podcasts, videos, websites and more.

“Our work doesn’t stop with medical affairs,” notes Daniel Leonard, former CEO of Scientific Commercialization, and current Member of the Board of The CM Group focused on Corporate Development. “While development of scientific and clinical stories during the early stages are key initial steps in a complex commercialization journey, it goes beyond that. Continued optimization of all relevant communication channels and connecting the right people with the right information is paramount to success. Joining forces with The CM Group’s family of companies is the right step to be able to serve our clients throughout the product lifecycle and I am excited to support this next chapter for both companies.”

Learn more about The CM Group and its Scientific Commercialization division.


Anne Tommasi

error: Content is protected !!